Effects of the Tangningtongluo formula as an alternative strategy for diabetics via upregulation of insulin receptor substrate-1 Corrigendum in /10.3892/mmr.2019.10649

Cheng,Long; Song,Junmei; Li,Geng; Liu,Yue; Wang,Yuming; Meng,Xiangbao; Sun,Guibo; Sun,Xiaobo

doi:10.3892/mmr.2017.6679

Effects of the Tangningtongluo formula as an alternative strategy for diabetics via upregulation of insulin receptor substrate-1

Corrigendum in: /10.3892/mmr.2019.10649

Authors:
- Long Cheng
- Junmei Song
- Geng Li
- Yue Liu
- Yuming Wang
- Xiangbao Meng
- Guibo Sun
- Xiaobo Sun
View Affiliations

Affiliations: Pharmacology and Toxicology Center, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, P.R. China, Department of Clinical Pharmacy, Baoji People's Hospital, Baoji, Shaanxi 721000, P.R. China, Integrative Medicine Center for Cardiovascular Disease, China‑Japan Friendship Hospital, Beijing 100029, P.R. China, Cardiovascular Disease Centre, Xiyuan Hospital, China Academy of Traditional Chinese Medicine, Beijing 100091, P.R. China, Department of Oncology, The Affiliated Hospital of Chifeng University, Chifeng, Inner Mongolia 024005, P.R. China
Published online on: June 1, 2017 https://doi.org/10.3892/mmr.2017.6679
Pages: 703-709
Copyright: © Cheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tangningtongluo (TNTL), a traditional Chinese medicine, has been widely used in clinics for decades in southwest China. Its pharmacological properties and underlying molecular mechanisms remain unclear. The main goal of ethnopharmacology is to identify novel bioactive compounds derived from plants for use in indigenous medical practice. This knowledge can be used to develop novel pharmaceuticals. In the present study, hyperglycemic C57BL/KsJ‑db/db (db/db) mice were used to test the effect of TNTL on microvasculature of the retina and hypoglycemia. Metformin (Met) was selected as a positive control. 26‑week‑old mice were randomly assigned to receive either the anti‑diabetic agent Met [140 mg/kg body weight (BW)], 1.8, 0.9 or 0.45 g/kg BW TNTL, or a placebo. The fasting blood glucose, serum insulin and glycated hemoglobin levels were measured. Histopathologic examination of the pancreas was performed to confirm the hypoglycemic effect. Fluorescein angiography was applied to detect diabetes‑induced retinal angioma in the db/db mice. TNTL intake significantly decreased the fasting blood glucose level in a dose‑dependent manner. Additionally, TNTL intervention resulted in a significant decrease in the insulin resistance index. Notably, TNTL treatment markedly reduced the speed of retinal degeneration and mildly reversed microvascular caliber degeneration. Western blot analysis indicated that upregulation of phosphorylated insulin receptor substrate‑1 (p‑IRS‑1) by the administration of TNTL may be strongly involved in the improvement of insulin resistance. In conclusion, TNTL exerted a strong hypoglycemic effect and reversed retinal degeneration via upregulation of ISR‑1. The present findings provide important scientific evidence supporting TNTL as an effective alternative approach for the management of Type 2 diabetes mellitus.

View Figures

View References

1	Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH and Hu FB: Diabetes in Asia: Epidemiology, risk factors, and pathophysiology. Jama. 301:2129–2140. 2009. View Article : Google Scholar : PubMed/NCBI
2	Chan JC, Zhang Y and Ning G: Diabetes in China: A societal solution for a personal challenge. Lancet Diabetes Endocrinol. 2:969–979. 2014. View Article : Google Scholar : PubMed/NCBI
3	Ning G and Bloomgarden Z: Diabetes in China: Prevalence, diagnosis, and control. J Diabetes. 5:3722013. View Article : Google Scholar : PubMed/NCBI
4	Weng J and Bi Y: Diabetes in China: The challenge now. J Diabetes Investig. 1:170–171. 2010. View Article : Google Scholar : PubMed/NCBI
5	L'Heveder R and Nolan T: International Diabetes Federation. Diabetes Res Clin Pract. 101:349–351. 2013. View Article : Google Scholar : PubMed/NCBI
6	Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, et al: Prevalence of diabetes among men and women in China. N Engl J Med. 362:1090–1101. 2010. View Article : Google Scholar : PubMed/NCBI
7	Yu S, Sun Z, Zheng L, Guo X, Yang H and Sun Y: Prevalence of Diabetes and Impaired Fasting Glucose in Hypertensive Adults in Rural China: Far from Leveling-Off. Int J Environ Res Public Health. 12:14764–14779. 2015. View Article : Google Scholar : PubMed/NCBI
8	Hu D, Sun L, Fu P, Xie J, Lu J, Zhou J, Yu D, Whelton PK, He J and Gu D: Prevalence and risk factors for type 2 diabetes mellitus in the Chinese adult population: The InterASIA Study. Diabetes Res Clin Pract. 84:288–295. 2009. View Article : Google Scholar : PubMed/NCBI
9	Hu D, Fu P, Xie J, Chen CS, Yu D, Whelton PK, He J and Gu D: MS for the InterASIA Collaborative Group: Increasing prevalence and low awareness, treatment and control of diabetes mellitus among Chinese adults: The InterASIA study. Diabetes Res Clin Pract. 81:250–257. 2008. View Article : Google Scholar : PubMed/NCBI
10	Jia W: Diabetes: A challenge for China in the 21st century. Lancet Diabetes Endocrinol. 2:e6–e7. 2014. View Article : Google Scholar : PubMed/NCBI
11	Chi C, Lee JL, Lai JS, Chen SC, Chen CY and Chang SK: Utilization of Chinese medicine in Taiwan. Altern Ther Health Med. 3:40–53. 1997.PubMed/NCBI
12	Hesketh T and Zhu WX: Health in China. Traditional Chinese medicine: One country, two systems. BMJ. 315:115–117. 1997. View Article : Google Scholar : PubMed/NCBI
13	Pang B, Zhou Q, Zhao TY, He LS, Guo J, Chen HD, Zhao LH and Tong XL: Innovative thoughts on treating diabetes from the perspective of traditional Chinese medicine. Evid Based Complement Alternat Med. 2015:9054322015. View Article : Google Scholar : PubMed/NCBI
14	Tang C, Ye Y, Feng Y and Quinn RJ: TCM, brain function and drug space. Nat Prod Rep. 33:6–25. 2016. View Article : Google Scholar : PubMed/NCBI
15	Tong XL, Dong L, Chen L and Zhen Z: Treatment of diabetes using traditional Chinese medicine: Past, present and future. Am J Chin Med. 40:877–886. 2012. View Article : Google Scholar : PubMed/NCBI
16	Wang P, Xu Q, Sun Q, Fan FF, Guo XR and Guo F: Assessment of the reporting quality of randomized controlled trials on the treatment of diabetes mellitus with traditional chinese medicine: A systematic review. PLoS One. 8:e705862013. View Article : Google Scholar : PubMed/NCBI
17	Zhang TT and Jiang JG: Active ingredients of traditional Chinese medicine in the treatment of diabetes and diabetic complications. Expert Opin Investig Drugs. 21:1625–1642. 2012. View Article : Google Scholar : PubMed/NCBI
18	Jiang HL, Niu JJ, Zhang WF, Huang WJ, Zhou MY, Sha WJ, Li JY, Li FF, Zhu T, Xia X, et al: The role of central nervous system on hypoglycemia and the feasibility of the brain theory in traditional Chinese medicine on treatment of diabetes mellitus. J Integr Med. 12:1–6. 2014. View Article : Google Scholar : PubMed/NCBI
19	Lao L and Ning Z: Integrating traditional Chinese medicine into mainstream healthcare system in Hong Kong, China-A model of integrative medicine in the HKU-SZ Hospital. J Integr Med. 13:353–355. 2015. View Article : Google Scholar : PubMed/NCBI
20	Li Y, Wu T, Shang H and Yang K: all subcentres attending the Chinese EBM Working Meeting in December 2008: Strategies for promoting the development of evidence-based medicine in China. J Evid Based Med. 2:47–52. 2009. View Article : Google Scholar : PubMed/NCBI
21	Liao PY, Hsu PC, Chen JM, Chiang JY and Lo LC: Diabetes with pyogenic liver abscess-A perspective on tongue assessment in traditional Chinese medicine. Complement Ther Med. 22:341–348. 2014. View Article : Google Scholar : PubMed/NCBI
22	Lin YJ, Ho TJ, Yeh YC, Cheng CF, Shiao YT, Wang CB, Chien WK, Chen JH, Liu X, Tsang H, et al: Chinese herbal medicine treatment improves the overall survival rate of individuals with hypertension among type 2 diabetes patients and modulates in vitro smooth muscle cell contractility. PLoS One. 10:e01451092015. View Article : Google Scholar : PubMed/NCBI
23	Wu Q and Fan H: The research for the clinical curative effect through combing traditional Chinese medicine with insulin to cure diabetes. Pak J Pharm Sci. 27:(4 Suppl). S1057–S1061. 2014.
24	Cheng L, Meng XB, Lu S, Wang TT, Liu Y, Sun GB and Sun XB: Evaluation of hypoglycemic efficacy of tangningtongluo formula, a traditional Chinese Miao medicine, in two rodent animal models. J Diabetes Res. 2014:7454192014. View Article : Google Scholar : PubMed/NCBI
25	Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, et al: Evidence that the diabetes gene encodes the leptin receptor: Identification of a mutation in the leptin receptor gene in db/db mice. Cell. 84:491–495. 1996. View Article : Google Scholar : PubMed/NCBI
26	Kodama H, Fujita M and Yamaguchi I: Development of hyperglycaemia and insulin resistance in conscious genetically diabetic (C57BL/KsJ-db/db) mice. Diabetologia. 37:739–744. 1994. View Article : Google Scholar : PubMed/NCBI
27	Wallace TM, Levy JC and Matthews DR: Use and abuse of HOMA modeling. Diabetes Care. 27:1487–1495. 2004. View Article : Google Scholar : PubMed/NCBI
28	Poon TY, Ong KL and Cheung BM: Review of the effects of the traditional Chinese medicine Rehmannia Six Formula on diabetes mellitus and its complications. J Diabetes. 3:184–200. 2011. View Article : Google Scholar : PubMed/NCBI
29	Ji L, Tong X, Wang H, Tian H, Zhou H, Zhang L, Li Q, Wang Y, Li H, Liu M, et al: Efficacy and safety of traditional chinese medicine for diabetes: A double-blind, randomised, controlled trial. PLoS One. 8:e567032013. View Article : Google Scholar : PubMed/NCBI
30	Wei J, Wu R and Zhao D: Analysis on traditional Chinese medicine syndrome elements and relevant factors for senile diabetes. J Tradit Chin Med. 33:473–478. 2013. View Article : Google Scholar : PubMed/NCBI
31	Angiolillo DJ, Bernardo E, Zanoni M, Vivas D, Capranzano P, Malerba G, Capodanno D, Prandini P, Pasquali A, Trabetti E, et al: Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 58:30–39. 2011. View Article : Google Scholar : PubMed/NCBI
32	Suer Orkunoglu FE, Mergen H, Bolu E and Ozata M: Molecular scanning for mutations in the insulin receptor substrate-1 (IRS-1) gene in Turkish with type 2 diabetes mellitus. Endocr J. 52:593–598. 2005. View Article : Google Scholar : PubMed/NCBI
33	Zhang Y, Sun CM, Hu XQ and Zhao Y: Relationship between melatonin receptor 1B and insulin receptor substrate 1 polymorphisms with gestational diabetes mellitus: A systematic review and meta-analysis. Sci Rep. 4:61132014. View Article : Google Scholar : PubMed/NCBI
34	Karolina DS, Armugam A, Tavintharan S, Wong MT, Lim SC, Sum CF and Jeyaseelan K: MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One. 6:e228392011. View Article : Google Scholar : PubMed/NCBI